Latest / Vanguards of Healthcare by Bloomberg Intelligence / AliveCor’s Priya Abani Uses Amazon Experience to Democratize ECG Tech

Transcript

AliveCor’s Priya Abani Uses Amazon Experience to Democratize ECG Tech · Vanguards of Healthcare by Bloomberg Intelligence

0:18
Speaker 1: Welcome to another episode of the Vanguards of Healthcare series.
0:21
Speaker 1: My name is Matt Henrickson, the medical technology analyst at
0:25
Speaker 1: Bloomberg Intelligence, which is the in house equity research platform
0:28
Speaker 1: of Bloomberg LP. We are pleased to have with us
0:31
Speaker 1: today Pria A Bodie, CEO of a Live Core, a
0:34
Speaker 1: privately held medical device company developing AI enabled electro cardiogram
0:39
Speaker 1: or ECG sensors. Pria, thank you for joining us.
0:42
Speaker 2: Thank you so much for having me.
0:44
Speaker 1: And so, Pria, you've been at the Helm since twenty nineteen.
0:50
Speaker 1: But what was the career path that led you to
0:53
Speaker 1: your CEO role?
0:55
Speaker 2: Here A great question.
0:58
Speaker 3: So from an early age, JA had a passion for
1:01
Speaker 3: math and logic. I've said this before, but my father
1:05
Speaker 3: was the first person in my life to notice this spark.
1:08
Speaker 3: He taught me basic when I was just twelve year old,
1:12
Speaker 3: and I think it was almost like, you know, igniting
1:15
Speaker 3: your curiosity about complex yet simple systems and it's all
1:21
Speaker 3: about problem solving using technology.
1:23
Speaker 2: So I've had, you know, a.
1:26
Speaker 3: Long life, which you know talks about my age at
1:30
Speaker 3: semiconductor companies like Intel. I went ahead and worked at
1:35
Speaker 3: Amazon and I think Intel, and eventually Amazon basically, you know,
1:42
Speaker 3: kind of like taught me how technology interacts with the
1:45
Speaker 3: human experience. So at Amazon, I helped launch a product
1:49
Speaker 3: that became a household name. I think we're all we've
1:51
Speaker 3: all heard about Alexa. And it was not just about
1:56
Speaker 3: developing the product and scaling the product, it was all
1:59
Speaker 3: about customer ops session. So it's the idea that you
2:03
Speaker 3: don't build for the sake of tech, but you build
2:05
Speaker 3: to solve a friction point in a human's life, and like,
2:11
Speaker 3: you know, like it helps you start developing a pattern
2:15
Speaker 3: for scaling.
2:16
Speaker 2: And at Amazon.
2:18
Speaker 3: Specifically, we were talking about decoupling services from hardware. So
2:22
Speaker 3: when I, you know, started talking to the investors of
2:26
Speaker 3: a live core because I've been very fascinated by the
2:29
Speaker 3: healthcare delivery system, and you know what happens here. I
2:32
Speaker 3: saw this intersection of my background and AI and scale
2:38
Speaker 3: and then you know, like basically intersecting with a deeply
2:42
Speaker 3: meaningful mission and a very similar approach where you have
2:48
Speaker 3: pieces of hardware that collects sensor information about the patients,
2:53
Speaker 3: but then what do you do with that data and
2:55
Speaker 3: how do you use AI to make that data insightful,
2:59
Speaker 3: intelligent and give it back to the user.
3:02
Speaker 2: So that's kind of what we have been doing.
3:04
Speaker 3: So we build tools that put medical grade insights directly
3:08
Speaker 3: into patients' hands, enabling them to capture an ECG, you know,
3:13
Speaker 3: their butt pressure measurement anywhere, share results with their doctors
3:17
Speaker 3: and seconds, and then after that it's about actions and services.
3:22
Speaker 2: So this is like really exciting.
3:24
Speaker 3: You know, when I joined in twenty nineteen, Aliko was
3:27
Speaker 3: basically a hardware manufacturer, and today we're a premier AI
3:32
Speaker 3: powered heart health provider. So we've gone way past just
3:36
Speaker 3: you know, detecting simple arrhythmias, where now you know, we
3:41
Speaker 3: have now pushed over AI to the point where we
3:43
Speaker 3: identify life threatening conditions like heart attacks. And we had
3:48
Speaker 3: the courage to seek FDA clearance for all of this, right,
3:50
Speaker 3: so we moved from a one you know, trick one
3:56
Speaker 3: arrhythmia thing to enabling real time informed cardiac decisions that
4:02
Speaker 3: save lives every single day.
4:04
Speaker 1: It's quite a path at a live core, and you
4:07
Speaker 1: have taken to expand that technology. One of the things
4:11
Speaker 1: that caught my attention when you just you know, you
4:14
Speaker 1: talk about your time at Amazon is decoupling services from hardware,
4:18
Speaker 1: and that kind of sounds you know, as you were
4:20
Speaker 1: closing out your you know, your remarks about a live
4:22
Speaker 1: core and going from you know, the one arrhythmia to
4:26
Speaker 1: just enabling technology, what does the coupling servicing mean? And
4:33
Speaker 1: because that kind of kind of builds into that, how
4:35
Speaker 1: that technology or how you're able to expand that offering
4:39
Speaker 1: with a live core. So it seems like, you know,
4:42
Speaker 1: long story short is, how does that experience that Amazon
4:45
Speaker 1: help you with that transition into the cardiology sector.
4:48
Speaker 3: Yeah, so, I mean, historically cardiac monitoring has been episodic, right,
4:53
Speaker 3: so when a patient gets an ECG when they're physically
4:57
Speaker 3: in a clinic or wearing a bulky holter. And I
5:02
Speaker 3: think one of the things that I learned is if
5:06
Speaker 3: you provide a service, to provide the service should be
5:09
Speaker 3: provided twenty four to seven. It should not be just
5:13
Speaker 3: when the service provider is on or at a time
5:16
Speaker 3: between eight to five, Right, So you have to be
5:19
Speaker 3: you have to the patient or the customer has to
5:23
Speaker 3: be able to depend on the service no matter where
5:26
Speaker 3: they are on the planet and when they need it.
5:29
Speaker 3: So this is where the unmet need here is significant.
5:33
Speaker 2: Right.
5:33
Speaker 3: So, heart conditions like atal fibrillation are often you know, peroximals,
5:39
Speaker 3: which means that they come and go. So the patient
5:42
Speaker 3: isn't having an episode during that specific visit in the
5:45
Speaker 3: doctor's office, the condition goes undiagnosed. And that's where this
5:50
Speaker 3: whole concept of you know, having the device with you
5:53
Speaker 3: no matter where you are, providing that device in various
5:57
Speaker 3: form factors, which is, you know, gives you a choice
6:00
Speaker 3: of how you want to carry it.
6:01
Speaker 2: You want to carry in your wallet, you want to
6:03
Speaker 2: carry in your purse.
6:04
Speaker 3: You know, bringing all of that together is what beside
6:07
Speaker 3: you know, try to kind of like you know INNO
6:10
Speaker 3: waiting on and traditionally CG tools are very very cumbersome, right,
6:15
Speaker 3: so you've seen some of the pictures of things that
6:17
Speaker 3: it shows up in every single picture we think of
6:19
Speaker 3: a hospital wires at their sales, you know, obviously low
6:24
Speaker 3: patient compliance. It's also like creates an alarm in the patient, right,
6:28
Speaker 3: It's like alarm fit like both of the kindians and
6:30
Speaker 3: the patients. So there is a massive data gap that
6:34
Speaker 3: happens between doctors' visits for a patient. And this is
6:39
Speaker 3: the whole concept of what I learned of how do
6:42
Speaker 3: you you know, again, how do you take a certain
6:46
Speaker 3: set of sensors and you're currently you know, like having
6:49
Speaker 3: the patient be able to create the data for the sensor,
6:53
Speaker 3: but then you're constantly thinking about it when the patient
6:56
Speaker 3: is you know, doing other things.
6:57
Speaker 2: And that's the AI part of this. And the gap.
7:02
Speaker 3: Happens in the home monitoring right to your point, like
7:04
Speaker 3: symptoms happen, but there's no medical grade data captured to
7:09
Speaker 3: prove it. And this is where we came in thinking,
7:11
Speaker 3: you know what, as soon as the patient, whether they're
7:14
Speaker 3: in the hospital or outside the hospital, they should be
7:16
Speaker 3: able to collect data about their health heart health in
7:20
Speaker 3: particular of what is what we're looking at, and then
7:23
Speaker 3: we should be able to provide insights, actions and services
7:27
Speaker 3: to help, you know, get them to live a better life.
7:29
Speaker 1: Yeah, that's that's quite interesting. You know from my perspective too,
7:32
Speaker 1: it's like just being at you know, my annual physical
7:36
Speaker 1: and gain the twelve lead ECGs. That seems very burning
7:39
Speaker 1: from in the doctor's office alone, let alone you know,
7:42
Speaker 1: outside the hospital setting. But you know, we'll just ground
7:48
Speaker 1: ECG then the market and the patients you know, to start,
7:53
Speaker 1: because it's not just you know, one cardiac condition or
7:59
Speaker 1: another cardiac condition. There's several cardiac conditions ranging from atrial
8:03
Speaker 1: fibrillation to schemia, heart failure, all these things. So how
8:08
Speaker 1: should the listener ground just the you know, cardiac monitoring
8:14
Speaker 1: marketing in general, are there specific segments that are more
8:19
Speaker 1: you know, the larger opportunity, more important opportunity for these
8:23
Speaker 1: patients to be monitored, Just kind of how you view
8:27
Speaker 1: this overall market opportunity.
8:30
Speaker 2: Yeah, no, I think that's a great question.
8:32
Speaker 3: So we are seeing a massive shift towards remote patient monitoring, right,
8:37
Speaker 3: so patients no longer want to be confined to a
8:39
Speaker 3: hospital bed to feel safe. They want hospital great technology
8:43
Speaker 3: in their pocket. And then the trend is also moving
8:46
Speaker 3: from analog to digital and from wire to wireless, so
8:51
Speaker 3: we are moving away from just recording data to actually
8:54
Speaker 3: interpreting data in real time. And I think the biggest
8:57
Speaker 3: change is in the integration of AI enabled predictive and analytics.
9:03
Speaker 3: So we're moving from what I call reactive care is
9:06
Speaker 3: treating a heart attack, for example, to proactive care, which
9:10
Speaker 3: is detecting all the conditions and items that lead to one.
9:16
Speaker 3: And you know, payers and providers are embracing this shift
9:19
Speaker 3: as well because it's proven to reduce readmissions and lower
9:22
Speaker 3: the overall.
9:22
Speaker 2: Cost of care.
9:23
Speaker 3: So I think by catching a condition early at home
9:27
Speaker 3: or outside the hospital, we about thousands of dollars spend
9:29
Speaker 3: in emergency because it's later on. And then finally it
9:34
Speaker 3: comes to accessibility. Right, So traditional monitoring was limited by
9:37
Speaker 3: geography and specialist availability, and now when you're in a
9:41
Speaker 3: rural area or a major city, you have the same
9:44
Speaker 3: medical grade diagnostics in.
9:45
Speaker 2: The palm of your hands.
9:47
Speaker 3: So now, having said that at a broad level, I
9:50
Speaker 3: want to come back to a live core, right, So
9:52
Speaker 3: we're not just a device company. We're a connective tissue
9:55
Speaker 3: across the care continuum, from initial screening to long term
10:00
Speaker 3: chronic management. We kind of, like to your question, like
10:04
Speaker 3: we bridge the gap between I feel a palpitation and
10:09
Speaker 3: then I have a diagnosis. We want to empower physicians
10:12
Speaker 3: and patients with a stream of medical grade data, insights
10:16
Speaker 3: and actions. So now when you think about from a
10:19
Speaker 3: like a physician point of view, there are three scenarios, right,
10:23
Speaker 3: and where they kind of recommend our kinds of devices.
10:26
Speaker 3: So when a patient has intermittent symptoms of palputations dizi
10:31
Speaker 3: as often missed by Standard twenty four our technology, or
10:36
Speaker 3: if you had an ablation procedure or starting a new
10:40
Speaker 3: cardiac medication like you know, like an anti arithmets to
10:46
Speaker 3: ensure that heart rhythm remains stable. And then for high
10:50
Speaker 3: risk patients who need a safety net to monitor a
10:54
Speaker 3: fib recurrence or other life threatening changes over the long term.
10:57
Speaker 3: So the two categories of devices that you mentioned right,
11:00
Speaker 3: So Kardamabal six lead is the patient's everyday companion and
11:05
Speaker 3: sefety A cleared provides a much deeper view of the
11:09
Speaker 3: heart rhythm than you know any of the smart watchers
11:11
Speaker 3: out there. Allows doctors to see the rhythm specific intervals
11:16
Speaker 3: like QT interval from the patient's home.
11:20
Speaker 2: Then we have this next step.
11:22
Speaker 3: Of what we call es Cardiac Care, which is our
11:24
Speaker 3: Comprehensive Heart Health subscription and this offers one hundred This
11:29
Speaker 3: is offered and used by hundreds of thousands of members, right.
11:33
Speaker 2: But it gives you advanced.
11:35
Speaker 3: Features so you understand your heart health better. It gives
11:38
Speaker 3: you things like sinus rhythms, It gives you a more
11:41
Speaker 3: deeper evaluation of your We call it AI clinical AI
11:46
Speaker 3: within the company, but basically for you as a patient,
11:49
Speaker 3: it is what your heart is doing right now. That
11:53
Speaker 3: combined with blood pressure data, uh now can give you
11:57
Speaker 3: also a much broader range of heart conditions. And that's
12:00
Speaker 3: kind of what we are going towards, right, is how
12:03
Speaker 3: do you bring in more relevant sensor data into the
12:05
Speaker 3: mix when you talk about cardiacor to well lead. This
12:09
Speaker 3: is a whole different kind of a disruption, right, So
12:13
Speaker 3: this is a disruptor for the clinical environment which uses
12:17
Speaker 3: a revolutionary form factor, new form factor to bring hospital
12:22
Speaker 3: great diagnostics to a variety of care settings.
12:25
Speaker 2: So imagine a device.
12:26
Speaker 3: Which is basically it's a small park the size of
12:31
Speaker 3: your fingers or even smaller, and it's got one wire
12:35
Speaker 3: connected to it with five electrodes on It basically goes
12:38
Speaker 3: into a clinician's pocket and or a lap coat, right
12:43
Speaker 3: to use these precise word a lap coat pocket. And
12:47
Speaker 3: right now this is the text thirty nine cardiac conditions
12:50
Speaker 3: including heart attacks. So in medical terms like mis and
12:54
Speaker 3: a schemiask, this is what we have clearance for. We
12:58
Speaker 3: are very very you know, excited by the potential of
13:04
Speaker 3: all the places, the non traditional places where this device
13:08
Speaker 3: can now be used and we can be you know,
13:12
Speaker 3: helping save lives across the globe in places there are
13:16
Speaker 3: there are villages in certain continents, and there are and
13:19
Speaker 3: there is like literally I think, across the globe right
13:22
Speaker 3: now in the most countries, including in some places in
13:25
Speaker 3: our own country, where there is no access to a
13:29
Speaker 3: cardiologist for literally hundreds and thousands of miles.
13:33
Speaker 2: And the ability for any.
13:35
Speaker 3: Kind of a physician to have this kind of a
13:37
Speaker 3: device to detect things like heart attack is just going
13:39
Speaker 3: to be a game changer. That's what we believe in,
13:42
Speaker 3: and we do not believe in, you know, holding technology
13:45
Speaker 3: in certain places, in certain hospitals, price points are very
13:51
Speaker 3: inhibitive for people to use it across the globe, and
13:54
Speaker 3: that's what we're going after.
13:55
Speaker 1: Yeah, that's interesting, and let's let's let's dive into that
13:58
Speaker 1: because you know, I think, well, my my initial perception
14:04
Speaker 1: of a live core was a you know, after the
14:08
Speaker 1: almost and after the fact, and it's the long term
14:11
Speaker 1: follow up, and I believe my understanding is that was
14:15
Speaker 1: the Cardia Mobile six L device. But now you're bringing
14:18
Speaker 1: in this Cardia twelve L which is going to be
14:22
Speaker 1: in the physician's office. That allows then that physician, like
14:27
Speaker 1: you said, almost to use it like a stethoscope in
14:29
Speaker 1: his pocket and bring it out. Is that the right
14:31
Speaker 1: way to envision how those two technologies play out together.
14:37
Speaker 3: I mean, yes, your words are better than mine.
14:42
Speaker 1: Well, I was actually just I took the information that
14:44
Speaker 1: you just gave me. So that's always great. So let's
14:47
Speaker 1: let's let's talk about the cardia twelve l then, because
14:53
Speaker 1: that seems to be the the you know, the most
14:56
Speaker 1: recent catalysts. And you talked about thirty nine determination. I
15:01
Speaker 1: just also remember that there was earlier this month or
15:05
Speaker 1: last month, there was a new FDA clearance for five
15:09
Speaker 1: new cardiac determinations. Is that included in that thirty nine? Now?
15:13
Speaker 2: Yeah?
15:14
Speaker 1: How important is those five for the new thirty nine?
15:17
Speaker 1: And yeah, thirty nine is a lot of kids to have.
15:21
Speaker 1: But I'm curious, out of those thirty nine, which ones
15:23
Speaker 1: are your favorite children?
15:24
Speaker 2: Oh? My god, as a matter of fact, none of them,
15:28
Speaker 2: but all of them.
15:29
Speaker 3: So as of early twenties twenty six, as you know
15:32
Speaker 3: that we received clearance for additional five determinations, bringing the
15:37
Speaker 3: total we had thirty five before. And then with the
15:40
Speaker 3: additional determinations, we actually collapsed two into one. So we
15:44
Speaker 3: now have cleared for thirty nine Cardiact determinations, which is
15:48
Speaker 3: the broadest range in the industry, and these new indications
15:52
Speaker 3: are not just incremental, they are clinically vital. And if
15:57
Speaker 3: you think of the traditional twelve lead machine in the hospital,
16:00
Speaker 3: it identifies several rhythms and morphologies, but again comes with
16:05
Speaker 3: a complex set of wires. You need a very specialized
16:10
Speaker 3: training to use it. And the whole point that we're
16:13
Speaker 3: trying to do here is challenge that by expanding our
16:15
Speaker 3: AI to work with this reduced lead set and a
16:18
Speaker 3: single cable design to ultimately match the diagnostic breadth of
16:23
Speaker 3: the traditional machines without all the complexity that often slows
16:27
Speaker 3: down care. So we're empowering healthcare providers with unprecedented clinical
16:33
Speaker 3: dept in a compact, portable form factor. So let me
16:37
Speaker 3: get a little bit more geeky here. So by adding
16:41
Speaker 3: access deviations and specific rhythm modifiers, we are providing this
16:47
Speaker 3: full story of a twelve DCG. So it's really worth
16:51
Speaker 3: noting that we have already identified over four thousand cases
16:55
Speaker 3: of MIS, which is myocardial infraction heart attacks basically and
17:00
Speaker 3: the schemias since the twelve lead launch. So these new
17:04
Speaker 3: determinations there is sharpening our ability to catch the subtle
17:09
Speaker 3: precursors of those major events and then a couple other
17:13
Speaker 3: things that have been happening. Right There was a peer
17:15
Speaker 3: review study that was published in heart rythm or to.
17:19
Speaker 3: It showed CARDIAT twelve lead reduced ECG acquisition time by
17:23
Speaker 3: twenty nine percent. So when the device can automatically detect
17:27
Speaker 3: thirty nine conditions and seconds in our case precisely ten
17:30
Speaker 3: seconds is the reading that you require to you know,
17:33
Speaker 3: basically tell you what you're going through. It allows conditions
17:38
Speaker 3: in very busy urgent care or primary care clinics to
17:41
Speaker 3: act immediately rather than waiting for a technician or a
17:45
Speaker 3: bulky card or a separate appointment. So just think of,
17:49
Speaker 3: you know, all the efficiencies that we can be now
17:52
Speaker 3: providing for the patient where they don't have to leave
17:55
Speaker 3: this system, go to another building, set up another appointment.
17:58
Speaker 3: You can all be checked like on the spot. So
18:01
Speaker 3: I think we're continuing to push the boundaries mad of
18:03
Speaker 3: what can be achieved with the compact solution and simplifying
18:08
Speaker 3: the hardware is one thing, but deepening the intelligence along
18:12
Speaker 3: with it is the game changer. And we really want
18:15
Speaker 3: to bring high fidelity cardiac care outside hospital settings and
18:19
Speaker 3: in hospital settings to you know, whatever is best for
18:22
Speaker 3: the patient.
18:23
Speaker 1: Yeah, and that seems very important too when you think
18:25
Speaker 1: about you know, m I or myocardial infarction cases, is
18:28
Speaker 1: that you want to treat that as quickly as possible.
18:31
Speaker 1: And being able to get that in the first step
18:33
Speaker 1: instead of having to go through additional steps of testing
18:36
Speaker 1: and screening and everything seems like a very important step
18:39
Speaker 1: for those patients.
18:40
Speaker 2: Yes, thank you so much, thank you.
18:43
Speaker 1: Yeah, And so we talk about some of the other
18:46
Speaker 1: clinical data, and you know there's over you know, on
18:49
Speaker 1: your website. I noticed one hundred and seventy peer reviewed articles,
18:53
Speaker 1: and we talk about twenty nine percent reduction in some
18:57
Speaker 1: of these cases. What about what are what would you
19:00
Speaker 1: consider some of the other landmark studies for a live
19:03
Speaker 1: core you know, what is the information you're trying to
19:06
Speaker 1: get out there for the physician either you know, the
19:08
Speaker 1: cardiologists or sound like even sometimes these primary care physicians
19:11
Speaker 1: are the ones who benefit the most from getting access
19:14
Speaker 1: to this data.
19:15
Speaker 3: Yeah, I know, this is such an important question. So
19:18
Speaker 3: it is so wonderful too. I told my team just
19:23
Speaker 3: like about four years back, it's so wonderful to wake
19:26
Speaker 3: up every week of full see wake up every day,
19:30
Speaker 3: but like wake up and read yet another study that
19:34
Speaker 3: has been done using our device somewhere in the world
19:37
Speaker 3: which is published and we're not even aware of it until.
19:40
Speaker 2: It gets published.
19:40
Speaker 3: So that that's what happens when you build technology that
19:44
Speaker 3: people start trusting and you don't, you know, you keep like,
19:46
Speaker 3: you know, raising.
19:48
Speaker 2: The bar on yourself.
19:49
Speaker 3: So I'm obviously tremendously proud of the broad adoption of
19:53
Speaker 3: our technology, of the Cardia technology by clinical researchers. You
19:57
Speaker 3: said one seventy, but actually I think we're about two
20:00
Speaker 3: hundred and fifteen now, so two hundred and fifty period
20:02
Speaker 3: reviewed articles, and our data is the bedrock.
20:06
Speaker 2: Of clinical trust. Right. So to your question, the key
20:09
Speaker 2: teams that we.
20:12
Speaker 3: Track is clinical validation of Overard technology, which is very
20:16
Speaker 3: very important, but also the clinical adoption in novel new cases.
20:21
Speaker 3: So let me give you some examples, right. So, a
20:24
Speaker 3: landmark study for US is the twenty twenty one Climb
20:29
Speaker 3: in at All study demonstrating high clinical accuracy of the
20:32
Speaker 3: cardio Mobile six lead compared to the traditional twelve y DCGs,
20:37
Speaker 3: leading the authors to conclude that it is appropriate for
20:40
Speaker 3: both clinical medicine and clinical trials. So this is adoption
20:44
Speaker 3: of what we would otherwise think as a patient facing device,
20:48
Speaker 3: but it's it is of the level where it can
20:51
Speaker 3: now also be used within the hospital systems and for
20:54
Speaker 3: clinical trials.
20:54
Speaker 2: It is very important for the biopharma you know side
20:57
Speaker 2: of the world.
20:59
Speaker 3: With regard to use cases, we have seen cardia being
21:02
Speaker 3: used very effectively for broad atal fibrillation, early detection, post ablation,
21:08
Speaker 3: arrhythmam monitoring, and for diagnosis following emergency room visits. There's
21:12
Speaker 3: literally a study or multiple studies on each of these topics.
21:17
Speaker 3: Another one is a very powerful use case for cardia
21:20
Speaker 3: which was published in twenty twenty four by Megan Lebrec
21:24
Speaker 3: and team at Ohio Health where they use the cardia
21:28
Speaker 3: to monitor patients being started on anti arithmetic medicines medications
21:35
Speaker 3: at home. So typically this process requires a three day
21:38
Speaker 3: hospital state for monitoring of the QT interval, and the
21:42
Speaker 3: research has demonstrated that cardia was an effective and safe
21:45
Speaker 3: way to monitor patients at home, completely eliminating the need.
21:50
Speaker 2: For a costly hospital stay.
21:52
Speaker 3: So that was like all the six lead stuff, right,
21:57
Speaker 3: let me tell you what I'm most aucited about at
21:58
Speaker 3: twelve lead because that's up. So right now you're in
22:02
Speaker 3: the midst of a multi center international study called Saint Louis,
22:08
Speaker 3: but it's actually St.
22:10
Speaker 2: E l UIs.
22:12
Speaker 3: Two and what it stands for is smartphone twelve lead
22:17
Speaker 3: ECG utility in st elevation myocardial infarction.
22:23
Speaker 1: I can see the Saint Lewis Pod zero game to remember.
22:27
Speaker 3: Yes exactly, And this is being done with Maoclinic serving
22:31
Speaker 3: as the coordinating site in colab.
22:34
Speaker 2: What we're doing here matters.
22:36
Speaker 3: We are testing cardia twel lead is a substitute for
22:39
Speaker 3: a standard twelve lead ECG in identifying STEMI, which is
22:43
Speaker 3: a severe type of heart attack in patients with chest pain.
22:47
Speaker 3: So you can imagine this is a very pivotal study
22:51
Speaker 3: improving that a pocket sized solution can match the gold
22:55
Speaker 3: standard hospital equipment in a life or death situation.
22:58
Speaker 2: And we are expecting results later this year.
23:02
Speaker 3: Okay, So ultimately, robust clinical validation is very very important
23:07
Speaker 3: to build lasting trust and adoption of our solutions, and
23:10
Speaker 3: we continue to partner with leading researchers and academic institutions
23:15
Speaker 3: or pretty much on a worldwide basis to ensure that
23:18
Speaker 3: our technology is transferring care pathways and it sets like
23:22
Speaker 3: new global standards and hopefully motivating a lot of innovators
23:27
Speaker 3: to move forward in their journeys as well.
23:30
Speaker 1: Yeah, now that's interesting. Later this year makes me think
23:32
Speaker 1: either maybe not TCT because that's a transcatheter conference, but
23:36
Speaker 1: maybe AHA. Is that kind of the right thought process
23:40
Speaker 1: understanding that nothing is guaranteed in the timeline? But is
23:44
Speaker 1: that kind of a if I'm looking ahead, does AHA
23:48
Speaker 1: seem like a reasonable conference where that data may come out?
23:52
Speaker 2: I would hope, so you'd hope.
23:54
Speaker 1: So okay, Yeah there, I like that too. And you
23:57
Speaker 1: know what's also interesting, you know, you're talking about the
23:59
Speaker 1: gold standard. I'm just curious and they're getting into that
24:04
Speaker 1: geeky side again for us as how what what is
24:08
Speaker 1: the technology? What is the algorithm, hardware development, whatever it
24:13
Speaker 1: is that allows a live core to be able to
24:16
Speaker 1: generate this similar accuracy to the kind of traditional UH
24:20
Speaker 1: standard of care that is out there.
24:23
Speaker 3: It's it's it's basically when you train your algorithm on
24:29
Speaker 3: in our case, millions of ECGs, and you just you know,
24:35
Speaker 3: you keep as I said, you keep training, you submit
24:38
Speaker 3: it for clearance. Then you ultimately better yourself because you know,
24:44
Speaker 3: have so many users using it. You go back to
24:47
Speaker 3: the next version of the next version. There are certain
24:49
Speaker 3: algorithms I think you're on like version three. This is
24:52
Speaker 3: like basically raising the bar on yourselfs right. So that's
24:55
Speaker 3: it's just it's what you do with you know, standard
24:58
Speaker 3: neural networks. And I think we have a whole set
25:01
Speaker 3: of people and what we call the Clinical LII team
25:04
Speaker 3: that their focus is to get this better and better
25:06
Speaker 3: and better, and the more data you collect actually for
25:10
Speaker 3: example with the twelve lead now what we are doing
25:13
Speaker 3: with collecting data on MS and as che yas. Ultimately,
25:17
Speaker 3: I think over time, I'm talking about let's say over
25:21
Speaker 3: the next decade. You know, the goal for us is
25:24
Speaker 3: to become the gold standard because you know that that's
25:29
Speaker 3: kind of what we are on a mission to do here.
25:31
Speaker 1: It's amazing what we can do when you you know,
25:35
Speaker 1: aggregate all that data together because you know, once again
25:37
Speaker 1: talking about me going to my primary care physician for
25:41
Speaker 1: my annual physical, you know, I get twelve LEADCG. But
25:45
Speaker 1: that data just stays there and isn't being utilized for
25:48
Speaker 1: anything else. But the fact that we can be able
25:50
Speaker 1: to combine all this data together to see trends across
25:53
Speaker 1: millions and millions of patients seems to be the key
25:58
Speaker 1: inflection point for this type of AI enable technology.
26:02
Speaker 3: I think yours just spot on that's that's exactly what
26:06
Speaker 3: is happening, and there is there is a certain thing
26:08
Speaker 3: that's happening in diagnostics. But we can also do that
26:11
Speaker 3: in other pieces of you know, subscriptions, so for example, uh,
26:17
Speaker 3: just it's it's not about you know, I mean the
26:19
Speaker 3: goal is in healthcare the user experiences often and afterthought,
26:24
Speaker 3: but at a life core, we are built to listen
26:26
Speaker 3: and act. And I just want to use this you know,
26:30
Speaker 3: this question or this comment to actually say that every
26:33
Speaker 3: week of our heads of product technology and I read
26:37
Speaker 3: reviews on Amazon and Carder dot com. As a matter
26:40
Speaker 3: of fact, Morgan reads all of this as well. It's
26:43
Speaker 3: like tens of thousands of data points and the speed
26:47
Speaker 3: of improvement is unmatched because we have a direct to
26:49
Speaker 3: patient fulse So our customer service teams aren't just troubleshooting
26:54
Speaker 3: hardware or you know, they're helping a seventy five year
26:56
Speaker 3: old feel confident that they just successfully captured a medical
26:59
Speaker 3: grade ECG. The onboarding and digital ux is made to
27:05
Speaker 3: ensure that from the moment you.
27:06
Speaker 2: Open the box, the de friction is near zero.
27:10
Speaker 3: And this is kind of the Amazon one click philosophy
27:13
Speaker 3: that we have applied to Hot Health, and we get
27:17
Speaker 3: a lot of ideas from our customers and I just
27:20
Speaker 3: don't see many people saying that in the industry, but
27:23
Speaker 3: we do. If you read over reviews, many of the
27:25
Speaker 3: things that you've implemented are things that have our customers
27:28
Speaker 3: have asked us to implement. Right, It's like, what happens
27:31
Speaker 3: after I'm detective with AFIF? What do you want me
27:33
Speaker 3: to do? Should I sit down? Should I drink water?
27:36
Speaker 3: Should I, you know, call my spouse or my children?
27:39
Speaker 3: Should I rush through the eer?
27:40
Speaker 2: Like?
27:40
Speaker 3: What am I supposed to do? So there are actions
27:43
Speaker 3: that are needed. And then on top of that, I
27:46
Speaker 3: want to see a cardiologist. But my arrhythmia came and
27:50
Speaker 3: went away, and my next appointment that I'm getting is
27:53
Speaker 3: in six months, and I'm not feeling peace of mind?
27:56
Speaker 2: What do you want me to do?
27:58
Speaker 3: And this is how we came up with our service,
28:00
Speaker 3: which provides a twenty four to seven cardiologist access across
28:04
Speaker 3: all fifty states. And now we're kind of like duplicating
28:06
Speaker 3: that on a global basis, because when you're feeling something you.
28:11
Speaker 2: Don't want to wait for six months to get a
28:12
Speaker 2: clarity on that.
28:14
Speaker 3: And that's why, you know, like making sure that we
28:18
Speaker 3: are a healthcare company with the clinical rigor of the
28:22
Speaker 3: you know, for example, the thirty nine FPA clearances, the
28:25
Speaker 3: two fifty plus period reviewed studies. And on the other side,
28:29
Speaker 3: we are a consumer tech company that understands engagement and
28:32
Speaker 3: habit formation. So when you bring all of this together,
28:37
Speaker 3: including the human back services, the human expert services, I
28:41
Speaker 3: think it goes beyond the you know, the storing the
28:45
Speaker 3: data and getting the AI to get better. I think
28:48
Speaker 3: that's that is such a critical aspect of what we do.
28:51
Speaker 3: But it is basically in my mind, step one, the
28:55
Speaker 3: providing the entire continuum is where we want to you know,
28:58
Speaker 3: continue to win the patient trust and also the clinicians trust,
29:02
Speaker 3: to be honest.
29:04
Speaker 1: Yeah, it sounds very interesting, you know, combining both the
29:08
Speaker 1: medical side, the FDA side of you know, this type
29:11
Speaker 1: of technology with the consumer side and the cardiac care.
29:14
Speaker 1: The subscription plan also kind of interesting how your background
29:19
Speaker 1: in Amazon seems to be playing very well with this
29:22
Speaker 1: subscription package side of the business. What's interesting is, you know,
29:27
Speaker 1: we talked about investments that's being made in the clinical
29:29
Speaker 1: data we talked about that Saint Louis data that should
29:31
Speaker 1: be coming out later this year. Because you have this
29:35
Speaker 1: hybrid business model. What are some of the investments you're
29:38
Speaker 1: making in that customer service experience you talked about the
29:43
Speaker 1: twenty four to seven doctor. Is it something where you're
29:46
Speaker 1: expanding the training of those doctors or you're expanding the
29:48
Speaker 1: number of physicians that are available to these patients. Are
29:51
Speaker 1: there other investments that you're making to kind of make
29:54
Speaker 1: that experience, you know, a better experience as the you know,
29:58
Speaker 1: as the patients provide their insight on some of the technology.
30:02
Speaker 4: Yeah, I think there are investments basically across the line
30:06
Speaker 4: of everything you said, right, So I do the good
30:09
Speaker 4: part of learning customer obsession in big tech is you
30:13
Speaker 4: never leave it there.
30:14
Speaker 3: You kind of imbib it and then you live with
30:17
Speaker 3: it for the rest of your life. And I think
30:19
Speaker 3: the advantage I have is I brought it to a
30:21
Speaker 3: mission where the stakes are measured in life saved, which
30:25
Speaker 3: is just nothing, but you know, just the grace of
30:28
Speaker 3: God to have this job, to be honest. So, in healthcare,
30:32
Speaker 3: the user experiences, as I mentioned too often and after
30:37
Speaker 3: thought and what we have done is built a company
30:40
Speaker 3: that continues to listen and act. So starting with the
30:44
Speaker 3: customer where you know, they have access to the hardware,
30:48
Speaker 3: and obviously the AI determinations to things like I am,
30:53
Speaker 3: you know, my heart is you know, feeling palpitations, but
30:58
Speaker 3: the device is telling me or the AI is telling
31:01
Speaker 3: me that I'm feeling nor I should be feeling normal?
31:04
Speaker 3: Can I send this to a cardiologist for an overview
31:06
Speaker 3: overweat That's the first service we actually built, and we've
31:11
Speaker 3: gone through millions of overheats right now just in the
31:14
Speaker 3: United States, and we're expanding that as you can imagine
31:17
Speaker 3: to other parts of the world.
31:19
Speaker 2: And then the next thing.
31:20
Speaker 3: Is how do I get access to actual cardiologists to
31:23
Speaker 3: have a conversation about my heart health? And then on
31:27
Speaker 3: the on you know, the AI side is we're not
31:31
Speaker 3: retaining subscribers just by storing the data, right, We retain
31:35
Speaker 3: them by continuing to innovate, by offering you insights, providing
31:41
Speaker 3: actionable you know, peace of mind, and to your point
31:46
Speaker 3: like getting the getting the data. You know, the more
31:49
Speaker 3: data we get, the better of our algorithms. Uh. And
31:53
Speaker 3: which goes back to why people do a lot of
31:56
Speaker 3: these you know, peer reviewed studies using our technology because
31:59
Speaker 3: they can depend on what we're doing and they see
32:02
Speaker 3: us kind of raising.
32:04
Speaker 2: The bar on ourselves.
32:05
Speaker 3: So I think by time at Amazon taught me to
32:08
Speaker 3: build ecosystems, not just products. And then when you move
32:12
Speaker 3: from a device to kind of an indispensable service like
32:16
Speaker 3: Cardia care, you aren't just selling a gadget, right, You're
32:20
Speaker 3: providing a lifelong heart health partner.
32:23
Speaker 2: And the one comment I.
32:25
Speaker 3: Want to make here is we have recently started doing
32:27
Speaker 3: webinars as a company, and I am just blown away
32:32
Speaker 3: by the number of people who sign up for the
32:35
Speaker 3: webinars and the numbers of questions that we get and
32:39
Speaker 3: how the community is interacting with each other. And it's
32:43
Speaker 3: it's an investment to you know put in So it's
32:46
Speaker 3: like it's like almost like one upon AI kind of
32:49
Speaker 3: an investments.
32:50
Speaker 2: It's a it's a human presence.
32:52
Speaker 3: It's like, you know, the the product leaders that tech
32:55
Speaker 3: leaders are given the webinars, the medical professionals are giving
32:58
Speaker 3: the webinars, and the skin is the number of people
33:01
Speaker 3: who joined the webinars and the kinds of questions they
33:04
Speaker 3: have and the openness of which we can answer the
33:07
Speaker 3: questions are very very heartwarming to see, which tells me
33:11
Speaker 3: that our biggest challenge in the world is going to
33:14
Speaker 3: be educating the patient based on everything that we have built.
33:20
Speaker 2: I think we are still on.
33:22
Speaker 3: Like step one of what we have built and just
33:24
Speaker 3: getting that adopted, and there is so much more we
33:26
Speaker 3: have built since then.
33:28
Speaker 1: Well, that's interesting because let's let's dive into that. They
33:30
Speaker 1: expand you know, spreading the word about what a life
33:33
Speaker 1: Core brings, especially because there's so much technology out there
33:38
Speaker 1: now that is providing general wellness kind of tool sets
33:42
Speaker 1: for these patients. And then they you know, kind of
33:46
Speaker 1: going with the FDA. Then there is you know, the
33:49
Speaker 1: recent change to their guidance that kind of eased regulation
33:54
Speaker 1: on these digital health products for general wellness. Just kind
34:00
Speaker 1: of curious what your thoughts are on kind of this,
34:03
Speaker 1: you know shift by the FDA and how you're kind of,
34:06
Speaker 1: let's say that hybrid business model of having FDA regulated
34:11
Speaker 1: devices for a kind of consumer level type of subscription
34:16
Speaker 1: base plays or benefits from those kind of changes.
34:21
Speaker 3: Yeah, let me answer the question in two parts, but
34:25
Speaker 3: really they're all connected, just like your question. Right, So
34:28
Speaker 3: a few years back, we were the only ones in
34:31
Speaker 3: this space, then the big tech giants entered. While some
34:36
Speaker 3: saw this as a threat, I think it was actually
34:39
Speaker 3: a massive validator of the space. Right, like health outside
34:43
Speaker 3: the hospital is here to stay and people want to
34:47
Speaker 3: be empowered, So like ECG became a household zone now
34:52
Speaker 3: and again I know there is a lot of people
34:54
Speaker 3: who have not yet reached, but millions of people are
34:57
Speaker 3: still habituated and looking at their hearthhealth now. So when
35:00
Speaker 3: you look at the landscape, I think we're now looking
35:03
Speaker 3: at two types of companies right one is the wellness weariables,
35:08
Speaker 3: and then the other is the clinical diagnostics. So most
35:12
Speaker 3: smart watches are single lead devices designed for general screening
35:17
Speaker 3: detecting a fib only, and they're now giving you know,
35:20
Speaker 3: they're giving alerts for other kinds of things including like
35:24
Speaker 3: you know, hypertension for example. We have very very consciously
35:29
Speaker 3: stayed focused on the medical side. So we're building a
35:32
Speaker 3: hospital in your pocket that clinicians actually trust for diagnosis.
35:37
Speaker 3: And a smart watch gives the doctors one view of
35:39
Speaker 3: the heart of our six lead gives them six views
35:43
Speaker 3: all of that. Like, I can go on right on
35:44
Speaker 3: the features, but I think what is happening is the.
35:47
Speaker 2: Top of the funnel.
35:49
Speaker 3: The number of companies now playing in the wellness arena
35:52
Speaker 3: has gone up, and as more people from you know,
35:57
Speaker 3: as electronics get cheaper, that's that's the only direction it
36:00
Speaker 3: goes in. I think there's going to be more and
36:02
Speaker 3: more entrance, there's going to be patent wars, there's going
36:05
Speaker 3: to be all kinds of things that happen there. But
36:07
Speaker 3: the fact is that the patient or the consumer is
36:11
Speaker 3: going to benefit because they'll have a lot of data
36:13
Speaker 3: at their disposal. But I think the problem is going
36:16
Speaker 3: to be what do they do with all of this data?
36:18
Speaker 4: Right?
36:19
Speaker 3: And that's where we basically, as I mentioned with the
36:23
Speaker 3: twelve lead, the really differentiator for us is our AI intelligence.
36:28
Speaker 3: So we are going definitely about very specific cardiac conditions,
36:33
Speaker 3: and we're providing a level of detail in a device
36:36
Speaker 3: that is against smaller, easier to use comparable to like
36:41
Speaker 3: a fifteen thousand dollars device. And the whole thing is like,
36:45
Speaker 3: you don't want the data just to sit on somebody's phone, right,
36:47
Speaker 3: you want that data to flow in the physician's workflow.
36:50
Speaker 3: So there's a lot of work that needs to happen
36:53
Speaker 3: in bridging this gap between a consumer friendly device and
36:56
Speaker 3: like a high fidelity clinical tool, and then is the
37:00
Speaker 3: reinbursement workflow son now think of it, right, a company
37:03
Speaker 3: like ours that has been so focused on medical diagnostics,
37:07
Speaker 3: we are still trying to figure out this whole workflow thing.
37:10
Speaker 3: And now you suddenly have like you know, eight different
37:13
Speaker 3: types of wellness devices, which is collecting a lot of
37:16
Speaker 3: other information. A lot of it is really good information,
37:20
Speaker 3: but again not something specific that a patient can do
37:23
Speaker 3: something with it. How does that flow into the system
37:26
Speaker 3: and what is a high fidelity piece of data and
37:28
Speaker 3: what is not? All of that is yet to be determined.
37:31
Speaker 3: But let me go back to your question about the FDA, right, So,
37:35
Speaker 3: I think the policies that they're making are very promising
37:39
Speaker 3: for the industry. What we like to do is we
37:42
Speaker 3: I think it's critical that we distinguish between wellness data
37:46
Speaker 3: and clinically valid metrics. And this helps again ensure actionable
37:52
Speaker 3: outcomes and prevent clinicians from being overburdened.
37:56
Speaker 2: By digital noise.
37:57
Speaker 3: So as more and more wellness technolology and data fall
38:01
Speaker 3: under enforcement discretion, I think the risk remains that the
38:05
Speaker 3: noise could overwhelm clinical workflows, and I think that's where
38:11
Speaker 3: to truly benefit patients and clinicians. It is critical that
38:14
Speaker 3: only clinically valid, medical grade technology is used to inform
38:19
Speaker 3: like EHRs and clinical decisions and everything else should be
38:23
Speaker 3: used in the right way, by the way, in a
38:25
Speaker 3: very important way for us to maintain our own health
38:29
Speaker 3: and you know, our own metrics as an individual.
38:32
Speaker 1: Yeah, no, it's interesting. It's gonna be interesting to see
38:35
Speaker 1: how this plays out. Especially with my takeaway from this.
38:39
Speaker 1: The new FDA guidance is that you still need the
38:41
Speaker 1: FDA approved device to actually do the diagnose and treatment
38:45
Speaker 1: and cure of a disease. And so basically it kind
38:48
Speaker 1: of turns into an increased awareness if more devices are
38:53
Speaker 1: out there for detecting atual fibrillation, but there're can still
38:58
Speaker 1: have to go with the doctor to say, hey, I
39:00
Speaker 1: got this symptom, I got my watch is telling me this,
39:03
Speaker 1: My ring is telling me that, and the doctor's like, well,
39:06
Speaker 1: that's great, let's put you on. Let's let's actually use
39:08
Speaker 1: an FDA approved device to test you out, which you know,
39:13
Speaker 1: and then turns into the potential for using the cardia
39:16
Speaker 1: at twelve L. And then we talked about reimbursement as well.
39:19
Speaker 1: So I'm kind of just first let's just jump into
39:22
Speaker 1: what is the Cardia twelve L reimbursement policy, because it's
39:26
Speaker 1: it's it's one tool, but is there a reimbursed per
39:29
Speaker 1: time it's used?
39:31
Speaker 3: Let me give a little bit new answer your So
39:33
Speaker 3: the introduction of category three codes, but the AMA was
39:37
Speaker 3: a critical stepping stone and these codes were created specifically
39:41
Speaker 3: for emerging AI power technologies, but they kind of serve
39:46
Speaker 3: as a bridge to broader adoption. What we have found
39:50
Speaker 3: as part of our ongoing engagement with clinicians is that
39:54
Speaker 3: because the twelve lead, the Cardiat twelve lead provides a
39:57
Speaker 3: high fidelity medical grade twelve LEADS output, it also fits
40:02
Speaker 3: within the existing Category one CPD codes, So like ninety
40:06
Speaker 3: three thousand, ninety three h five ninety three oh one
40:10
Speaker 3: zero the doctors have used for decades.
40:13
Speaker 2: So yes, right now this is per ACG.
40:17
Speaker 3: And the thing is in the hospital setting. Reimbursement is
40:21
Speaker 3: the language of adoption. So by filling into existing WORKFLOWCE
40:25
Speaker 3: and payment structures, we've removed the single biggest barrier for
40:29
Speaker 3: health systems. They don't have to change the way they
40:32
Speaker 3: build and they just get to change how to deliver care. Again,
40:37
Speaker 3: in our case, moving from the bulky card to a
40:39
Speaker 3: device that fits in a pocket. So our commitment is
40:43
Speaker 3: to ensure clinicians don't have a deal duplicator or confusing
40:46
Speaker 3: AI codes. We are proving that our AI isn't an
40:50
Speaker 3: add on, it's a core component of a modern efficient
40:54
Speaker 3: to E LEAD system. And you know, when it comes
40:57
Speaker 3: to it, reinbursement just isn't about revenue, right, it is
41:01
Speaker 3: about democratizing access. It means a rural clinic or a
41:06
Speaker 3: noncology office can now afford to provide the same level
41:10
Speaker 3: of cardiac screening as a major hospital just because the
41:14
Speaker 3: financial path is already paved. So that that's kind of
41:17
Speaker 3: the way we look at it. And I think when
41:19
Speaker 3: it comes down to it, payers all prefer using existing
41:23
Speaker 3: CPD codes when they accurately describe a servers because it
41:26
Speaker 3: preserves their stable, comparable budget neutral you know, budget payment
41:32
Speaker 3: plan instead of fragmenting things with duplicative codes. So that's
41:36
Speaker 3: kind of where we are with a.
41:37
Speaker 1: Twelve need Okay, And then how does the rest of
41:40
Speaker 1: the business model play out with that subscription fee? I mean,
41:44
Speaker 1: how much of your business model relies on that CMS
41:48
Speaker 1: reimbursement versus the monthly subscription pay and then if we
41:52
Speaker 1: look out into the future, is there a potential where
41:56
Speaker 1: there's enough clinical and economic benefit to show that this
42:00
Speaker 1: monthly subscription could potentially be reimbursed by the CMS.
42:04
Speaker 2: I hope all your works come true.
42:08
Speaker 3: So consumer subscriptions for US drive long term engagement and data,
42:14
Speaker 3: while CMS reimbursement drives long term, large scale clinical adoption.
42:20
Speaker 3: Right so we see them as two engines powering the
42:22
Speaker 3: same mission right now, and ultimately, of course we would want,
42:27
Speaker 3: you know, we will you know, basically go and have
42:31
Speaker 3: enough data to show that we should get reimbursement across
42:34
Speaker 3: our services. But right now, Kardiacare is a direct to
42:37
Speaker 3: patient engine. It builds a lifelong habit of hot health.
42:42
Speaker 3: We obviously have FSA, you know, I just say that
42:45
Speaker 3: a user can use to pay for it. But the
42:47
Speaker 3: goal is it provides a predictable, high margin revenue for US,
42:52
Speaker 3: very typical of a tech company. On the CMS side,
42:56
Speaker 3: the CMS reimbursement is of a scale engine. So by
42:59
Speaker 3: aligning with established CMS codes, we make it easy for
43:03
Speaker 3: health systems to adopt our tech at massive scale and
43:08
Speaker 3: to be honest aliving, you know, aligning of our products
43:11
Speaker 3: and clinical services with these established codes and payment systems.
43:15
Speaker 3: Again to your point, it enables rapid provider adoption, supports
43:20
Speaker 3: competitive post positioning, and creates a scalable revenue engine for
43:25
Speaker 3: US both in the US and Europe and as we
43:28
Speaker 3: expand to different countries. Obviously, my goal is to provide
43:32
Speaker 3: all of the services that we provide these, you know,
43:35
Speaker 3: to the citizens of United United States across the globe
43:38
Speaker 3: as well. So as you know, we mentioned twelve lead
43:43
Speaker 3: ECG is currently used as a point of care and
43:46
Speaker 3: the service provider uses the ACG as a tool for
43:49
Speaker 3: clinical decision making. In the future, Like you know, as
43:53
Speaker 3: as we collect longitudinal data on the customer or the
43:57
Speaker 3: physician collects that data, there are so many other things
43:59
Speaker 3: that can help happen on prediction of you know, what
44:03
Speaker 3: is happening to that particular patient. So we don't necessarily
44:07
Speaker 3: see the investment replacing subscriptions, but ultimately that is where
44:13
Speaker 3: we want it to be, you know, so that we
44:16
Speaker 3: can scale, we can scale faster and provide these life
44:19
Speaker 3: saving technologies to as many people as we can.
44:23
Speaker 1: Yeah, and you know, as we close out this episode,
44:27
Speaker 1: what are some of the developments that have been done
44:29
Speaker 1: at a live core kind of like the next generation
44:32
Speaker 1: of devices. And one of the thing that's always interesting
44:35
Speaker 1: to me is you see some of these other technology
44:37
Speaker 1: out there and wearable patch forms. Is that something that's
44:40
Speaker 1: on your radar? And then you know, just to close
44:43
Speaker 1: out completely, is you know a lot of development has
44:46
Speaker 1: occurred in this You know six seven years that you've
44:49
Speaker 1: been the CEO of a live core, but it seems
44:52
Speaker 1: like things could accelerate even faster the next five years.
44:55
Speaker 1: So as you're looking out ahead with your product development,
44:58
Speaker 1: with your reimbursement, the clinical data, where do you see
45:02
Speaker 1: a live core and just cardiac monitoring and being in
45:05
Speaker 1: the whole hospital infrastructure in five years.
45:09
Speaker 2: It's a great question.
45:10
Speaker 3: So we're continuously working to strength and the underlying AI
45:14
Speaker 3: powering over a cardia solutions. The goals for us is,
45:18
Speaker 3: of course we now have clearance with thirty nine, but
45:20
Speaker 3: you can imagine we want to match what is already
45:23
Speaker 3: in the hospital and in the future add more determinations
45:27
Speaker 3: which are not even available in the traditional devices that
45:32
Speaker 3: are formed today. The other very very big opportunity we
45:36
Speaker 3: have is what works on the twelve lead, how much
45:40
Speaker 3: of that can be ported For example, to over six
45:43
Speaker 3: lead device.
45:44
Speaker 2: What can we provide directly to the patients.
45:46
Speaker 3: Of course, all of this for US comes with FDA
45:49
Speaker 3: clearance and working very closely for the FDA for this.
45:52
Speaker 3: We don't have plans for a new variable form factor
45:54
Speaker 3: at the moment, but I we're constantly on the lookout.
46:00
Speaker 3: There are so many comorbid situations that we're looking at
46:04
Speaker 3: along with a patient being you know, a cardiac patient
46:08
Speaker 3: that would benefit from different types of data. I'm just
46:12
Speaker 3: watching it this very carefully, so we don't like bring
46:15
Speaker 3: in like you know, sensor data from five different things,
46:17
Speaker 3: but really don't know clinically what to do with it.
46:20
Speaker 3: And that's what we that's why we're watching U. There
46:22
Speaker 3: is as you know, there is rings, there is risks,
46:26
Speaker 3: there is patches, There is all kinds of things being
46:28
Speaker 3: developed right now. So I think, and it's fantastic, this
46:33
Speaker 3: is what we want to have happen. But then again
46:36
Speaker 3: it comes down to, you know, intelligent companions that recognize
46:41
Speaker 3: subtle changes over time, help people take preventive action before
46:46
Speaker 3: a condition emerges. And then imagine a connected system right
46:50
Speaker 3: that can automatically someone help in an emergency situation or
46:55
Speaker 3: notify a care team the moment intervention is required. That's
46:59
Speaker 3: kind of what we are going for right now. But
47:01
Speaker 3: when you look at a whole like a whole person situation,
47:05
Speaker 3: which is what we are, like, I don't think of
47:08
Speaker 3: one person as a patient of this one thing. So
47:11
Speaker 3: you have related conditions diabetes, high perension, sleep, by the way,
47:16
Speaker 3: a huge thing here. So how do we create a
47:19
Speaker 3: single integrated ecosystem for whole person care And what are
47:24
Speaker 3: the diagnostics from each one of these disciplines that we
47:28
Speaker 3: can bring together to do something meaningful. That's what I
47:32
Speaker 3: think is going to be the future. And just to
47:37
Speaker 3: make a point here, I don't think the surprise will
47:40
Speaker 3: be in the technology, but I think the surprise will
47:43
Speaker 3: be in how quickly we realize we no longer have
47:45
Speaker 3: to wait for symptoms to take action. And I'm just
47:49
Speaker 3: so glad to see that we're moving away from the
47:52
Speaker 3: sick care business to a well care era or decades
47:57
Speaker 3: or a century where early detection and proactive interventions has
48:00
Speaker 3: become the norm.
48:02
Speaker 1: Yeah. No, it's gonna be a very exciting several years.
48:04
Speaker 1: And you know, I look forward to seeing how live
48:06
Speaker 1: Core develops a products starting with the st Louis trial
48:09
Speaker 1: later this year, but pria, thank you for joining us today.
48:12
Speaker 1: I appreciate you coming in.
48:14
Speaker 3: Thank you so much for having me, I truly appreciate it.
48:17
Speaker 1: And thank you to our listeners for tuning in today.
48:20
Speaker 1: We hope you join us for future episodes, and if
48:22
Speaker 1: you'd like to stay up to date, you can click
48:24
Speaker 1: the subscribe button on Spotify or your favorite streaming platform.
48:27
Speaker 1: Take care,